TY-302

TYK Medicines, Inc · Phase 1 active Small molecule

At a glance

Generic name	TY-302
Sponsor	TYK Medicines, Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） (PHASE1, PHASE2)
A Study of TY-302 in Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TY-302 CI brief — competitive landscape report
TY-302 updates RSS · CI watch RSS
TYK Medicines, Inc portfolio CI